The results demonstrated that patients with NAFLD had significantly higher RBP4 concentrations (37.9 ± 6.8 μg/ml) than did those with non-NAFLD (35.0 ± 6.7 μg/ml) (P < 0.001). The gene discussed is RBP4; the disease is metabolic dysfunction-associated steatotic liver disease.